Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab in Patients With Resectable Tumors

• Status: Not yet recruiting
• Trial end date: 2028-03-01

Summary

This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indications.

• Phase: Phase 2

Details

• Lead Sponsor: IO Biotech
• Collaborators: Almac; Theradex
• Treatments: Pembrolizumab